Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;6(1):131-140.
doi: 10.1007/s41030-020-00113-w. Epub 2020 Mar 16.

Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis

David M G Halpin  1 , Eckard H Hamelmann  2   3 , Peter A Frith  4 , Petra M Moroni-Zentgraf  5 , Benjamin van Hecke  6 , Anna Unseld  5 , Huib A M Kerstjens  7   8 , Stanley J Szefler  9
Affiliations

Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis

David M G Halpin et al. Pulm Ther. 2020 Jun.

Abstract

Introduction: Airway obstruction is usually assessed by measuring forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and peak expiratory flow (PEF). This post hoc study investigated comparative responses of lung function measurements in adults and adolescents (full analysis set, N = 3873) following treatment with tiotropium Respimat®.

Methods: Lung function outcomes were analysed from five phase III trials in adults (≥ 18 years) with symptomatic severe, moderate and mild asthma (PrimoTinA-asthma®, MezzoTinA-asthma® and GraziaTinA-asthma®, respectively), and one phase III trial in adolescents (12-17 years) with symptomatic moderate asthma (RubaTinA-asthma®). Changes from baseline versus placebo in FEV1, FVC, PEF and FEV1/FVC ratio with tiotropium 5 µg or 2.5 µg added to at least stable inhaled corticosteroids at week 24 (week 12 in GraziaTinA-asthma) were analysed.

Results: All lung function measures improved in all studies with tiotropium 5 µg (mean change from baseline versus placebo), including peak FEV1 (110-185 mL), peak FVC (57-95 mL) and morning PEF (15.8-25.6 L/min). Changes in adolescents were smaller than those in adults, and were statistically significant primarily for FEV1 and PEF, but not for FVC.

Conclusion: Consistent improvements were seen across all lung function measures with the addition of tiotropium to other asthma treatments in adults across all severities, whereas the improvements with tiotropium in adolescents primarily impacted measures of flow rather than lung volume. This may reflect less pronounced airway remodelling and air trapping in adolescents with asthma versus adults.

Trial registration: ClinicalTrials.gov NCT01172821 NCT01172808 NCT01257230 NCT01316380.

Keywords: Airway obstruction; Asthma; Muscarinic antagonist; Respiratory function tests; Tiotropium bromide.

Plain language summary

Asthma is characterised by problems with the way that the lungs work, particularly narrowing of the airways. Doctors can measure the effect of asthma on someone’s breathing in different ways. We looked to see whether these different methods work for different people with asthma, and whether treatment affects all measurements in a similar way. Lung function was measured after treatment with a drug that opens the airways (tiotropium), and comparisons were made between adults and adolescents with asthma. We also looked at people with severe asthma and those whose asthma was less severe. Tiotropium improved all the measures of lung function in both age groups and across severities. One measure improved more in adults than in adolescents. This may be because adolescents had better lung function at the start and thus less room for improvement, or because the adolescents had not had asthma for as long, and so may have had less long-term damage to their airways than adults.Trial Registration Numbers: NCT00772538, NCT00776984, NCT01172808, NCT01172821, NCT01316380, NCT01257230.

PubMed Disclaimer

References

    1. Global Initiative for Asthma. Global strategy for asthma management and prevention (2019 report). 2019 [cited October 29, 2019]. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-J....
    1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi: 10.1183/09031936.05.00034805. - DOI - PubMed
    1. Francisco B, Ner Z, Ge B, Hewett J, Konig P. Sensitivity of different spirometric tests for detecting airway obstruction in childhood asthma. J Asthma. 2015;52(5):505–511. doi: 10.3109/02770903.2014.984842. - DOI - PubMed
    1. Quanjer PH, Stanojevic S, Stocks J, Hall GL, Prasad KV, Cole TJ, et al. Changes in the FEV(1)/FVC ratio during childhood and adolescence: an intercontinental study. Eur Respir J. 2010;36(6):1391–1399. doi: 10.1183/09031936.00164109. - DOI - PubMed
    1. Szefler SJ, Murphy K, Harper T, Boner A, Laki I, Engel M, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;140:1277–1287. doi: 10.1016/j.jaci.2017.01.014. - DOI - PubMed

Associated data

LinkOut - more resources